Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 27, 2011

View Archived Issues

Avila Therapeutics describes new BTK inhibitor

BF-200 ALA shows efficacy in treating actinic keratosis in advanced studies

Influenza HA1-flagellin fusion vaccines well tolerated in healthy volunteers

GlaxoSmithKline presents novel TRPV4 channel antagonists

New agents for HCV infection synthesized by Vertex Pharmaceuticals

Orphan drug status for Atox Bio's AB-103

FDA clears kit to aid in determining AML prognosis

Conatus Pharmaceuticals terminates phase II CTS-1027 study

Celiac disease candidate therapy completes proof-of-principle phase II study

Phase II trial evaluates fingolimod in Japanese patients with MS

NIH grant awarded for AEOL-10150 as medical countermeasure against nerve agents

High Point Pharmaceuticals claims new beta-secretase inhibitors

Studies assess [11C]-choline PET/CT as prostate cancer staging tool

Poxel reports encouraging phase II data on imeglimin

Immunovaccine clear to start phase I/II DPX-Survivac trial in Canada

New conjugated neuroactive steroids disclosed in U.S.

Novel soluble guanylate cyclase activators described by Merck & Co.

Ajinomoto prepares novel calcium-sensing CaS receptor agonists

Bristol-Myers Squibb and Gilead Sciences enter licensing agreement for antiretroviral regimen

AtheroNova completes pre-IND meeting with FDA on atherosclerosis therapy

Solasia Pharma begins study of darinaparsin injection in Japan

S*BIO plans phase III program for pacritinib

Phase III study finds Latuda noninferior to Seroquel XR

Bionovo opens enrollment for pivotal trial of Menerba

FDA extends PDUFA action date for dapagliflozin NDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...